Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depo...

Descripción completa

Detalles Bibliográficos
Autores principales: Arunogiri, Shalini, Lintzeris, Nicholas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711199/
https://www.ncbi.nlm.nih.gov/pubmed/33303254
http://dx.doi.org/10.1016/j.jsat.2020.108221
_version_ 1783618097127620608
author Arunogiri, Shalini
Lintzeris, Nicholas
author_facet Arunogiri, Shalini
Lintzeris, Nicholas
author_sort Arunogiri, Shalini
collection PubMed
description The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.
format Online
Article
Text
id pubmed-7711199
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Published by Elsevier Inc.
record_format MEDLINE/PubMed
spelling pubmed-77111992020-12-03 Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges Arunogiri, Shalini Lintzeris, Nicholas J Subst Abuse Treat Article The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment. Published by Elsevier Inc. 2021-05 2020-12-03 /pmc/articles/PMC7711199/ /pubmed/33303254 http://dx.doi.org/10.1016/j.jsat.2020.108221 Text en © 2020 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Arunogiri, Shalini
Lintzeris, Nicholas
Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title_full Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title_fullStr Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title_full_unstemmed Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title_short Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges
title_sort depot buprenorphine during covid-19 in australia: opportunities and challenges
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7711199/
https://www.ncbi.nlm.nih.gov/pubmed/33303254
http://dx.doi.org/10.1016/j.jsat.2020.108221
work_keys_str_mv AT arunogirishalini depotbuprenorphineduringcovid19inaustraliaopportunitiesandchallenges
AT lintzerisnicholas depotbuprenorphineduringcovid19inaustraliaopportunitiesandchallenges

Ejemplares similares